Screening for coronary artery disease in asymptomatic individuals: Why and how?

Philippe Degrell, Emmanuel Sorbets, Laurent J Feldman, Philippe Gabriel Steg, Gregory Ducrocq

Journal: Archives of cardiovascular diseases 2016;108(12):675-82

PMID: 26596251

Free Full Text on Elsevier Science View on PubMed

Abstract

Cardiovascular disease is still the main cause of death in the world, and coronary artery disease is the largest contributor. Screening asymptomatic individuals for coronary artery disease in view of preventive treatment is therefore of crucial interest. Apart from established risk scores based on traditional risk factors such as the Framingham or SCORE risk scores, new biomarkers and imaging methods have emerged (high-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2 and secretory phospholipase A2, coronary artery calcium score, carotid intima-media thickness and ankle-brachial index). Their added value on top of the classic risk scores varies considerably and the most convincing evidence exists for coronary artery calcium score in intermediate-risk asymptomatic individuals.

Address: Département hospitalo-universitaire fibrose, inflammation, remodelage (FIRE), French Alliance for Cardiovascular clinical Trials (FACT) and F-CRIN network, université Paris-Diderot, Sorbonne Paris Cité, Paris, France; Hôpital Bichat and hôpital Avicenne, Assistance publique-Hôpitaux de Paris, hôpitaux universitaires Paris Nord Val-de-Seine, Paris, France; Inserm U-1148, Paris, France.; Département hospitalo-universitaire fibrose, inflammation, remodelage (FIRE), French Alliance for Cardiovascular clinical Trials (FACT) and F-CRIN network, université Paris-Diderot, Sorbonne Paris Cité, Paris, France; Hôpital Bichat and hôpital Avicenne, Assistance publique-Hôpitaux de Paris, hôpitaux universitaires Paris Nord Val-de-Seine, Paris, France; Inserm U-1148, Paris, France; National Heart and Lung Institute, Royal Brompton Hospital, London, United Kingdom.; Département hospitalo-universitaire fibrose, inflammation, remodelage (FIRE), French Alliance for Cardiovascular clinical Trials (FACT) and F-CRIN network, université Paris-Diderot, Sorbonne Paris Cité, Paris, France; Hôpital Bichat and hôpital Avicenne, Assistance publique-Hôpitaux de Paris, hôpitaux universitaires Paris Nord Val-de-Seine, Paris, France; Inserm U-1148, Paris, France. Electronic address: [email protected].

DOI: 10.1016/j.acvd.2015.10.001